Cancers (Jul 2023)

Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know

  • Matthew D. Robinson,
  • Mairéad G. McNamara,
  • Hamish W. Clouston,
  • Paul A. Sutton,
  • Richard A. Hubner,
  • Juan W. Valle

DOI
https://doi.org/10.3390/cancers15153781
Journal volume & issue
Vol. 15, no. 15
p. 3781

Abstract

Read online

As part of routine cancer care, patients may undergo elective surgery with the aim of long-term cure. Some of these patients will receive systemic anti-cancer therapy (SACT) in the neoadjuvant and adjuvant settings. The majority of patients, usually with locally advanced or metastatic disease, will receive SACT with palliative intent. These treatment options are expanding beyond traditional chemotherapy to include targeted therapies, immunotherapy, hormone therapy, radionuclide therapy and gene therapy. During treatment, some patients will require surgical intervention on an urgent or emergency basis. This narrative review examined the evidence base for SACT-associated surgical risk and the precautions that a surgical team should consider in patients undergoing SACT.

Keywords